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In order to determine the prevalence of vancomycin-resistant enterococci (VRE) in The Netherlands, 624
hospitalized patients from intensive care units or hemato-oncology wards in nine hospitals and 200 patients
living in the community were screened for VRE colonization. Enterococci were found in 49% of the hospitalized
patients and in 80% of the patients living in the community. Of these strains, 43 and 32%, respectively, were
Enterococcus faecium. VRE were isolated from 12 of 624 (2%) and 4 of 200 (2%) hospitalized patients and
patients living in the community, respectively. PCR analysis of these 16 strains and 11 additional clinical VRE
isolates from one of the participating hospitals revealed 24 vanA gene-containing, 1 vanB gene-containing, and
2 vanC1 gene-containing strains. All strains were cross-resistant to avoparcin but were sensitive to the novel
glycopeptide antibiotic LY333328. Genotyping of the strains by arbitrarily primed PCR and pulsed-field gel
electrophoresis revealed a high degree of genetic heterogeneity. This underscores a lack of hospital-driven
endemicity of VRE clones. It is suggested that the VRE in hospitalized patients have originated from unknown
sources in the community.
Enterococcus spp. have recently emerged as important nos-
ocomial pathogens (35). According to the data from the Na-
tional Nosocomial Infections Surveillance System, enterococci
are the fourth leading cause of nosocomial infections in the
United States (12). Enterococcal infections that have fre-
quently been reported include urinary tract infections, bacte-
remia, endocarditis, intra-abdominal infections, and surgical
wound infections (27). Enterococcus faecalis is commonly iso-
lated from the human gastrointestinal tract, whereas Entero-
coccus faecium is less frequently isolated from that site (31).
This latter species, however, is noted for its antimicrobial re-
sistance. Vancomycin-resistant E. faecium (VREF) strains
have emerged in a setting of increasing high-level resistance of
enterococci to penicillins and aminoglycosides (28). During the
last few years, nosocomial outbreaks due to VREF have been
described (17, 25). The emergence of VREF has raised serious
concerns (28), and in response, the Hospital Infections Control
Practices Advisory Committee (HICPAC), in collaboration
with the Centers for Disease Control and Prevention, has de-
veloped recommendations for preventing the spread of vanco-
mycin-resistant enterococci (VRE) (18). Given the concern
that vancomycin resistance genes may transfer from entero-
cocci to Staphylococcus aureus, a phenomenon that has been
observed in vitro (31), control measures have already been
proposed, should vancomycin-resistant S. aureus strains even-
tually arise (10).
The microbiology laboratory has an important role in the
detection, reporting, and control of VRE. The HICPAC doc-
ument emphasizes the need for routine susceptibility testing of
all enterococci isolated from clinical specimens. Furthermore,
in hospitals where VRE have not yet been detected, periodic
culture surveys of stools or rectal swabs of patients at high risk
for VRE infection or colonization are indicated (18). In The
Netherlands, no systematic study has been done to evaluate the
prevalence of VRE infection or colonization in hospitalized
patients or patients living in the community. Therefore, the
present study was started to determine the prevalence of fecal
carriage of VRE in hospitalized patients with an increased risk
for infection or colonization with VRE and in patients living in
the community. We determined the susceptibility of VRE to
vancomycin, teicoplanin, avoparcin (a glycopeptide available
throughout Europe as an additive in animal feed [15]), and
LY333328 (a new glycopeptide antibiotic [37]). In order to
determine the genetic basis of the glycopeptide resistance phe-
notype, PCR assays aimed at the various resistance genes were
performed. Moreover, the VRE were typed by pulsed-field gel
electrophoresis (PFGE), arbitrarily primed PCR (AP-PCR),
and ribotyping to determine the degree of genetic relatedness
of this group of resistant microorganisms.
MATERIALS AND METHODS
Prevalence study. Five Dutch university hospitals in Rotterdam, Utrecht,
Nijmegen, and Amsterdam and four regional teaching hospitals in Breda and
Tilburg participated in the study. Six hundred twenty-four patients who were
hospitalized in the following wards were screened for gastrointestinal carriage of
VRE: medical and surgical intensive care unit (ICU), thoracic surgical ICU,
neurological and neurosurgical ICU, pediatric ICU (either surgical, neonatal, or
general pediatric), and hemato-oncology wards. The prevalence study was car-
ried out in November 1995 and February 1996. In addition, 200 outpatients
attending general practitioners for diarrhea were screened. For this latter group
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of patients no information was available on prior antibiotic exposure. Early and
empiric treatment of bacterial diarrhea in patients living in the community is
uncommon practice in The Netherlands.
Bacterial isolates. Sixteen strains of VRE isolated during the prevalence study
were analyzed. Four of these 16 strains were isolated at Rotterdam University
Hospital (hospital A). In addition, 11 clinical strains of VRE that were isolated
in 1995 in hospital A before the start of the survey were studied. The 11 strains
were isolated from patients with rectal colonization but without infection (n 5 5),
whereas the other strains were clear causes of nosocomial infection (urinary tract
infections [n 5 2], cholecystitis [n 5 2], and soft tissue infection and peritonitis
[n 5 2]).
Culture and identification. Stool specimens or rectal swabs from all patients
were cultured in a selective, esculin-containing enrichment broth (1, 26) supple-
mented with 50 mg of cephalexin per liter and 75 mg of aztreonam (Bristol-
Myers Squibb, Princeton, N.J.) per liter. All esculin-positive broth cultures were
subcultured on a new selective agar designed for isolation of E. faecium (14), with
and without 6 mg of vancomycin per liter, and on Columbia blood agar. In a pilot
study this procedure proved to be sensitive, very convenient, and easy since all
broth cultures containing enterococci did turn black; all other broth cultures
could be disregarded without further processing. All enterococcus-like, arabi-
nose-fermenting, and arabinose-nonfermenting colonies were subcultured. A
presumptive identification of Enterococcus was made on the basis of colonial
morphology. Gram staining result, catalase and PYRase (Difco Laboratories,
Detroit, Mich.) activities, and the presence of the Lancefield group D antigen
(13). Definitive identification was done with the API 32 rapid system (Bio-
Me´rieux, Marcy l’Etoile, France). Enterococcus gallinarum was identified by
digestion of DNA with SmaI and PFGE. Strains for which all DNA fragments
were ,200 kb on PFGE were identified as E. gallinarum (7).
Susceptibility testing. Resistance to vancomycin was detected by the E-test
(AB Biodisk, Solna, Sweden) (34). An inoculum with a turbidity equivalent to
that of a 0.5 McFarland standard and Mueller-Hinton agar (Difco) were used.
Plates were read after incubation at 37°C for 24 h, and the MICs obtained by the
E-test were rounded to the nearest higher doubling dilution. All vancomycin-
resistant enterococci (MICs, .4 mg/liter) were subjected to further susceptibility
tests by standard agar dilution and broth dilution methods according to the
guidelines of the National Committee for Clinical Laboratory Standards (NC-
CLS) (29). E. faecalis ATCC 29212 and S. aureus ATCC 29213 were used as
reference strains. The following glycopeptide agents were tested: vancomycin
(Eli Lilly & Co., Indianapolis, Ind.), teicoplanin (MMDRI-Lepetit Research
Center, Gerenzano, Italy), avoparcin (Roche, Basel, Switzerland), and LY333328
(Eli Lilly & Co.).
DNA isolation. DNA was isolated as described by Boom et al. (4). The strains
were grown overnight at 37°C on brucella blood agar plates. Colonies were
suspended in TEG buffer (25 mM Tris-HCl [pH 8.0], 10 mM EDTA, 50 mM
glucose). A lysozyme solution (10 mg/liter) was added, and this mixture was
incubated for 1 h at 37°C. Guanidine hydrothiocyanate was added for cell lysis,
and Celite (Janssen Pharmaceuticals, Beerse, Belgium) was used for DNA bind-
ing. DNA was eluted with 10 mM Tris-HCl (pH 8.0). The DNA concentration
was estimated by electrophoresis on a 1% agarose gel (Hispanagar; Sphaero Q,
Leiden, The Netherlands) containing ethidium bromide in the presence of
known quantities of bacteriophage lambda DNA.
PCR assay for vanA, vanB, and vanC genes. The PCR assays were performed
as described earlier by Dutka-Malen et al. (9). Approximately 10 to 100 ng (10
ml) of DNA was added to a PCR mixture (90 ml) containing 10 mM Tris-HCl (pH
9.0), 50 mM KCl, 2.5 mM MgCl2, 0.01% gelatin, 0.1% Triton X-100, 0.2 mM
(each) the four deoxyribonucleotide triphosphates, and 1.2 U of Taq DNA
polymerase (Sphaero Q). Four different primer couples (vanA, vanB, vanC1, and
vanC2 [9]) were used in the assay (50 pmol of each primer per reaction mixture).
Amplification of DNA was performed in a Biomed model 60 thermocycler
(Biomed, Theres, Germany) by using predenaturation at 94°C for 2 min, fol-
lowed by 30 cycles of 1 min at 94°C, 1 min at 54°C, and 1 min at 72°C. Amplicons
were analyzed by electrophoresis on a 1% agarose gel (Gibco BRL, Brussels,
Belgium) containing ethidium bromide in the presence of a 100-bp ladder.
Ribotyping. Restriction digestion of 20-ml (5-mg) samples of DNA was done by
overnight incubation at 37°C with EcoRI (Boehringer GmbH, Mannheim, Ger-
many). DNA fragments were separated by electrophoresis on a 1% agarose gel
for 16 h (30 V, 200 mA). Southern transfers of the gel with EcoRI-digested DNA
were made by capillary blotting onto a nylon membrane (Hybond N1; Amer-
sham, Buckinghamshire, United Kingdom). The blots were hybridized with a 16S
rRNA riboprobe. The probe was synthesized by PCR-mediated amplification of
the ribosomal genes of Escherichia coli. The amplicon was purified by Qiaquick
procedures (Westburg, Leusden, The Netherlands) and labelled by using ECL
kits (Amersham). Further processing (hybridization, washing, and development)
was done according to the guidelines provided with the ECL kit.
AP-PCR. AP-PCR was performed as described before (40). Approximately 5
to 50 ng (10 ml) of DNA was added to a PCR mixture (40 ml) containing 10 mM
Tris-HCl (pH 9.0), 50 mM KCl, 2.5 mM MgCl2, 0.01% gelatin, 0.1% Triton
X-100, 0.2 mM (each) the deoxyribonucleotide triphosphates, and 1.2 U of Taq
DNA polymerase. Four different primers were used in separate assays (50 pmol
of primer per reaction mixture; ERIC-1R, 59-ATG TAA GCT CCT GGG GAT
TCA C-39; ERIC-2, 59-AAG TAA GTG ACT GGG GTG AGC G-39; AP-1,
59-GGT TGG GTG AGA ATT GCA CG-39; AP-7, 59-GTG GAT GCG A-39).
Amplification of DNA was performed in a Biomed model 60 thermocycler by
using predenaturation at 94°C for 4 min, followed by 40 cycles of 1 min at 94°C,
1 min at 25°C, and 2 min at 74°C. Banding patterns were visualized after
electrophoresis on a 1% agarose gel containing ethidium bromide in the pres-
ence of a 100-bp ladder. Banding patterns were interpreted by visual inspection.
Different types were identified on the basis of even a single differentiating DNA
fragment. Differences in ethidium bromide staining intensity were ignored.
PFGE. Ten colonies of an overnight culture grown on blood agar were sus-
pended in 100 ml of EET buffer (100 mM sodium EDTA, 10 mM EGTA, 10 mM
Tris-HCl [pH 8.0]). This suspension was mixed with 100 ml of 1% agarose (Incert
agarose; FMC Bioproducts Corp., Rockland, Maine), and the mixture was trans-
ferred into sample plug molds (final agarose concentration, 0.5%). The plugs
were incubated for 4 h at 37°C in 1 ml of EET buffer containing 10 mg of
lysozyme (Sigma Chemical Co., St. Louis, Mo.). This lysis solution was replaced
by a 1-ml EET buffer solution containing 1 mg of proteinase K and 1% sodium
dodecyl sulfate for a further overnight incubation at 37°C. The plugs were
washed six times (30 min each time at room temperature) in TE solution (10 mM
Tris-HCl [pH 8.0], 1 mM EDTA). To digest the DNA, a 5-mm slice of the sample
plug was placed in a TE solution (10 mM Tris-HCl [pH 8.0], 0.1 mM EDTA) with
40 U of SmaI (Boehringer GmbH), and the mixture was incubated overnight at
25°C. The plugs were loaded onto a 1% agarose gel (SeaKem GTG agarose;
FMC) in 0.53 TBE (Tris, borate, EDTA) (32). Electrophoresis was performed
with a CHEF DR II apparatus (Bio-Rad, Richmond, Calif.) programmed in the
auto-algorithm mode (block 1, run time of 8 h and switch time of 0.5 to 15 s;
block 2, run time of 10 h and switch time of 15 to 30 s). The gels were stained with
ethidium bromide for 15 min and were destained in distilled water for 1 h before
photography. All gels were inspected visually by two different investigators.
Profiles were designated by a different capital letter any time that a distinct
pattern (difference of four or more bands) was obtained. Isolates with identical
profiles were assigned the same letter. Isolates that differed by one to three
bands, consistent with a single genetic event, were assigned to a subtype (38).
Statistical analysis. Fisher’s two-tailed test was used to assess differences
between frequencies of isolation of enterococci in the two different patient
populations.
RESULTS
Three hundred six (49%) of the 624 hospitalized patients
and 161 (80%) of 200 diarrheic patients living in the commu-
nity carried enterococci in their gastrointestinal tracts (P ,
0.01). Of the 306 enterococci isolated from hospitalized pa-
tients, 132 (43%) were identified as E. faecium. Of 161 entero-
cocci from patients outside the hospital, 52 (32%) were iden-
tified as E. faecium (P , 0.05). Thus, E. faecium was isolated
from 132 of 624 (21%) of the hospitalized patients and 52 of
200 (26%) of the patients living in the community (P . 0.05).
VRE were isolated from 12 (2%) of the 624 hospitalized pa-
tients and 4 (2%) of the 200 patients living in the community.
Fifteen VRE were identified as E. faecium; one was identified
as E. faecalis. Fifteen (8%) of 184 E. faecium strains isolated in
the prevalence study were vancomycin resistant. In addition, 11
strains of VRE were isolated in hospital A at times separate
from the period of the prevalence study. Nine were identified
as E. faecium, and two were identified as E. gallinarum. Thus,
27 strains of VRE were available for further studies.
The susceptibilities of the 27 strains of VRE to vancomycin,
teicoplanin, avoparcin, and LY333328 and the resistance ge-
notype are presented in Table 1. Complete cross-resistance
between vancomycin and avoparcin was found. LY333328,
however, was 250- to .1,000-fold more active than vancomycin
against vanA VRE. Major discrepancies were observed be-
tween the MICs of LY333328 that were determined by the agar
dilution method and those determined by the broth dilution
method: on agar, the MIC of LY333328 at which 90% of
isolates are inhibited (MIC90) for vanA VRE was 4 mg/liter
(range, 0.25 to 4 mg/liter), whereas in broth the MIC90 was 0.5
mg/liter (range, 0.125 to 1 mg/liter). We did not observe such
differences with the other glycopeptide agents tested. Twenty-
four of the 27 strains of VRE, including all VRE from the
prevalence study, had the vanA genotype; 1 had the vanB
genotype, and 2 had the vanC1 genotype. For all vanA E.
faecium isolates vancomycin MICs were .256 mg/liter and
teicoplanin MICs were .64 mg/liter. For the vanB and vanC1
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strains the vancomycin MIC was 8 mg/liter and the teicoplanin
MIC was 0.5 mg/liter.
The restriction endonuclease patterns obtained by PFGE
with SmaI for the 27 strains of VRE are presented in Fig. 1. An
overview of all typing results is given in Table 2. The discrim-
inatory power of AP-PCR with primers AP-7 and ERIC-1 was
low compared to that with primers AP-1 and ERIC-2. There-
fore, only the results of AP-PCR with primers AP-1 and
ERIC-2 are presented in Table 2 (see also Fig. 2). Analysis of
all 27 strains of VRE revealed 23 different patterns by PFGE,
TABLE 1. In vitro activities of four glycopeptide agents against 27 strains of VREa
Strain group and
no. Species
MIC (mg/liter)b
van genotype
Van Tei Avo LY333328
Clinical isolatesc
10-a E. faecium .256 .256 .256 1 vanA
10-b E. faecium .256 .256 .256 0.5 vanA
10-c E. faecium .256 .256 .256 0.25 vanA
10-d E. faecium .256 .256 .256 0.5 vanA
10-e E. faecium .256 128 .256 0.5 vanA
10-f E. faecium .256 .256 .256 0.5 vanA
10-g E. faecium .256 .256 .256 0.25 vanA
10-h E. faecium .256 .256 .256 0.5 vanA
10-i E. gallinarum 8 0.5 8 0.25 vanC1
10-j E. faecium 8 0.5 8 0.25 vanB
10-k E. gallinarum 8 0.5 8 0.25 vanC1
Survey isolates
11-1c E. faecium .256 .256 .256 0.25 vanA
12-mc E. faecium .256 .256 .256 0.125 vanA
12-nc E. faecalis .256 .256 .256 0.25 vanA
12-oc E. faecium .256 .256 .256 0.125 vanA
21-p E. faecium .256 .256 .256 0.125 vanA
22-q E. faecium .256 .256 .256 1 vanA
22-r E. faecium .256 .256 .256 0.25 vanA
22-s E. faecium .256 128 .256 0.25 vanA
31-t E. faecium .256 .256 .256 0.25 vanA
32-u E. faecium .256 .256 .256 0.125 vanA
42-v E. faecium .256 .256 .256 0.125 vanA
52-w E. faecium .256 .256 .256 0.125 vanA
62-x E. faecium .256 .256 .256 0.125 vanA
62-y E. faecium .256 .256 .256 0.25 vanA
62-z E. faecium .256 .256 .256 0.25 vanA
62-a E. faecium .256 .256 .256 0.5 vanA
a In vitro activities were determined by a standard NCCLS broth dilution method.
b Van, vancomycin; Tei, teicoplanin; Avo, avoparcin. The breakpoints for vancomycin and teicoplanin defined by NCCLS are 4 and 8 mg/liter, respectively.
Breakpoints have not yet been defined for avoparcin and LY333328.
c Strains isolated in hospital A.
FIG. 1. Restriction endonuclease patterns obtained by PFGE with SmaI for 27 strains of VRE isolated from hospitalized patients and patients living in the
community in The Netherlands. From left to right, the strains appear in the lanes in the same order in which they are listed in Tables 1 and 2. Each strain has a two-digit,
one-letter code corresponding to the location (1, Rotterdam; 2, Amsterdam; 3, Breda; 4, Utrecht; 5, Nijmegen; 6, community), the screening (0, routine isolates from
hospital A; 1, prevalence study of November 1996; 2, prevalence study of February 1997), and strain letter code corresponding to the order of the strains listed in Tables
1 and 2. A 50-kb ladder (Bio-Rad, Veenendaal, The Netherlands) is shown in the lane on the right as a molecular size standard.
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17 by AP-PCR analysis with primers AP-1 and ERIC-2, and
only 7 by ribotyping (see Fig. 3 for some examples). Some
strains that were indistinguishable by AP-PCR were unrelated
by PFGE (e.g., strains 21-p and 12-o). Vice versa, AP-PCR was
able to distinguish strains that appeared to be highly related by
PFGE (e.g., strains 32-u and 62-a).
PFGE of 15 strains from hospital A yielded 15 different
patterns. PFGE of 16 strains of VRE from the prevalence
study (including four strains from hospital A) yielded 12 dif-
ferent patterns. Five strains isolated from patients hospitalized
in three different hospitals appeared to be closely related (Ta-
ble 2). These five strains could be divided into two different
subtypes by AP-PCR. Therefore, the combination of PFGE
and AP-PCR demonstrated genetic unrelatedness for 13 of 16
strains of VRE from the survey.
DISCUSSION
The rapid emergence of resistance in enterococci and the
increasing incidence of colonization and infection with VRE
have become health care issues that have caused serious con-
cern to physicians and health authorities alike (18).
This study documents the prevalence of intestinal coloniza-
tion of selected patients from ICUs and hemato-oncology
wards as well as of general practice patients in The Nether-
lands. Enterococci were found in 49% of the inpatients and
80% of the outpatients. This proportion of hospitalized pa-
tients who carry enterococci is lower than that found in previ-
ous studies, in which 75 to 90% of the patients carried these
microorganisms (31, 36). These latter studies screened uns-
elected hospitalized patients. One can speculate as to whether
greater use of penicillins like amoxicillin or the amoxicillin-
clavulanic acid combination may have occurred in our selected
group of patients and, thus, may have influenced the preva-
lence of enterococci isolated from the gastrointestinal tract.
We isolated E. faecium from 21% of the inpatients and 26% of
the outpatients, which is in agreement with previous findings of
E. faecium in 20 to 40% of stool cultures (3, 31). VRE were
isolated from 2% of the patients living in the community.
Several European studies have reported similar frequencies in
the community (21, 22). However, a much higher frequency
has been reported in a Belgian study (42). In the latter study,
11 (28%) of 40 volunteers living in the community who were
healthy, who were not health care workers, and who had not
received antibiotics for at least 1 year were colonized with
TABLE 2. Overview of PFGE, AP-PCR, and ribotyping results for
27 strains of VREa
Strain group
and no. Ribotype PFGE AP-PCR
b
Clinical isolatesc
10-a A A A
10-b B B B
10-c A C C
10-d A D D
10-e A E E
10-f B F B
10-g C G F
10-h A H G
10-i D I H
10-j A J I
10-k D K H
Survey isolates
11-1c E L J
12-mc A M K
12-nc F N L
12-oc C O M
21-p A M1 M
22-q C P K
22-r A Q K
22-s A M1 M
31-t A R N
32-u A M1 M
42-v C S O
52-w A T N
62-x A U M
62-y G V P
62-z A W Q
62-a A M1 K
a Note that the level of resolution of ribotyping is less than those seen for
PFGE and AP-PCR; the smallest number of individual types can be discerned.
The largest number of types was identified by PFGE. PFGE type M and M1 show
differences at less that three band positions.
b Based on AP-1 and ERIC-2 primers.
c Strains isolated in hospital A.
FIG. 2. AP-PCR fingerprints obtained with primers AP-1 (a) and ERIC-2 (b)
for 11 strains of VRE isolated from clinical samples. The lanes contain strains
that have been identified by letters (A to K) corresponding to strains 10-a to 10-k,
respectively, in Tables 1 and 2. The lane marked m contains molecular size
markers (100-bp ladder; Gibco BRL); the position of the 600-bp fragment is
indicated on the right. Interpretation of these experimental data is provided in
Table 2.
FIG. 3. Ribotypes of 16 strains of VRE isolated during the multicenter sur-
vey. The lanes contain strains have been identified by letters (L to a) corre-
sponding, from left to right, to strains 11-1 to 62-a, respectively, in Tables 1 and
2. The position of a 2,000-bp reference fragment is indicated on the right.
Interpretation of these experimental data can be found in Table 2.
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VRE. The results of North American studies performed in the
Houston, Texas, metropolitan area, however, contrast with the
European data, since VRE appeared to be absent from healthy
people in Houston (5). The level of colonization with VRE in
people in the community in Europe parallels the level of col-
onization of animals with these resistant organisms (6). Several
studies have now reported the absence of VRE from animals
and people in the community in the United States, in contrast
to the high frequencies in hospitals (5, 23, 39). Some investi-
gators, however, have cautioned against comparing the results
of the studies mentioned above, since differences in method-
ology could, at least in part, explain the observed differences in
isolation rates (5).
Since ICU patients and patients in oncology wards were
found to be at increased risk for infection or colonization with
VRE (18), we decided to select these patients for our inpatient
survey. The rate of isolation of VRE from these hospitalized
patients was 2% and, therefore, was similar to the rate of
isolation from outpatients. This is roughly in agreement with
the results of a recent Belgian study, in which it was shown that
3.5% of hospitalized patients were carriers of VRE (16). In
Finland, Suppola et al. (36) investigated hospitalized patients
with hematological malignancies and reported a prevalence of
VRE of 2%.
We analyzed the genetic relatedness of the 27 VRE strains
by PFGE and AP-PCR. In previous studies PFGE has been
shown to be the most discriminating technique for typing iso-
lates of VRE, and this technique is now considered the “gold
standard” (24, 25). Recently, however, AP-PCR has proven to
be a powerful typing tool as well. Results of PFGE and AP-
PCR are often in concordance (2). In our study, however,
PFGE was more discriminatory than AP-PCR. Combining the
data generated by the two methods, we demonstrated the ge-
netic unrelatedness of 13 of 16 strains of VRE isolated during
the survey and of all 15 strains that were isolated in hospital A.
No evidence of major inter- or intrahospital spread of VRE in
The Netherlands exists. This observation is remarkable since
no special infection control measures for preventing the trans-
mission of VRE were in place in the participating hospitals at
the time of the survey. Together with the observed isolation
rate of 2% for the patients living in the community, it is sug-
gested that VRE in hospitalized patients may have originated
from unknown sources in the community. The gastrointestinal
tract is probably the major reservoir in humans, from which
subsequent infection can eventually develop. This is in agree-
ment with a recent report from New York City (32). Food has
been proposed as a source (8, 28). Others have put forward
pets and other domestic animals (6, 41). Furthermore, the use
of antibiotics as feed additives for growth enhancement in
animals may be associated with the emergence of VRE (22).
An example of such a growth-promoting agent is avoparcin, a
drug that has been used in The Netherlands for a long time.
The production of pigs, poultry, and calves is an area of im-
portant economic activity in The Netherlands. To date, The
Netherlands country is one of the leading exporters of con-
sumer poultry products in the world, after the United States
and France (11). Although official figures are not available, it
is clear that avoparcin has been used in The Netherlands on a
very large scale. Preliminary results of a nationwide study of
the prevalence of VRE in poultry suggest that approximately
80% of the consumer poultry at the retail level is colonized
with VRE, possibly as a result of the unrestricted use of
avoparcin in the poultry industry (43). Thus, the use of oral
glycopeptide antibiotics in the animal production industry
should be strongly discouraged. Recently, the European Com-
munity committed itself to a cautious approach and banned all
use of avoparcin as feed additive in animals by 1 April 1997
(12a).
The emergence of VRE has resulted in an increase in the
incidence of infections that are caused by these organisms and
that cannot be treated with currently available antimicrobial
agents (19). LY333328 is a new semisynthetic glycopeptide that
has been reported to have increased activity against vancomy-
cin-resistant gram-positive microorganisms (30). In our study,
LY333328 was found to possess greatly enhanced activity
against VRE. In general, the MICs of LY333328 were 25- to
1,000-fold lower than those of vancomycin. These data are in
agreement with those presented in an earlier report (37). Sur-
prisingly, the MICs of LY333328 obtained by an agar dilution
method were four- to eightfold higher than those obtained by
a broth dilution method, but we do not have an explanation for
these discrepancies. This phenomenon has recently been re-
ported by others (20). The results, however, indicate that
LY333328 is a promising new drug that deserves further eval-
uation. In conclusion, we have shown in a multicenter study
that, first, VRE can be isolated from hospitalized patients and
patients living in the community in The Netherlands at a fre-
quency of 2%. Second, these strains appear to be unrelated,
and therefore, no evidence of major inter- or intrahospital
spread of VRE strains in The Netherlands exists. Third, our
data suggest that VRE are acquired outside the hospital envi-
ronment. Further studies are warranted to elucidate the origin
and the epidemiology of vancomycin resistance. In countries
with large populations of animal livestock, including The Neth-
erlands, where large quantities of feed additives are used, it
seems wise to strongly discourage the use of oral glycopeptides
not only in humans but in the animal production industry as
well.
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